Muzaffar Iqbal, MD
Medical Oncology · Overland Park, KSNPI 1699741306
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,442 of the $1,610 with a category attached, or 89.6%. 19 manufacturers reported payments, led by Pfizer at 32.3% of the total. That places this record below the midpoint for medical oncology clinicians in KS, where the typical reported total is $7,378.
Across 96 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$520
- AbbVie$142
- Merck$132
- E.r. Squibb & Sons, L.L.C.$108
- Bristol Myers Squibb$92
- Pharmacyclics LLC, An Abbvie Company$70
- plus $546 from 13 others
What the payments were for
- Food & beverage$1,44290%
- Education$16810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $520 |
| AbbVie | 6 | $142 |
| Merck | 7 | $132 |
| E.r. Squibb & Sons, L.L.C. | 8 | $108 |
| Bristol Myers Squibb | 5 | $92 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $70 |
| GSK | 4 | $67 |
| Stemline Therapeutics Inc. | 4 | $64 |
| Gilead(2 entities) | 4 | $61 |
| AstraZeneca | 3 | $53 |
| Johnson & Johnson | 2 | $52 |
| Genentech USA, Inc. | 3 | $52 |
| Array Biopharma Inc | 2 | $42 |
| Novartis | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Deciphera Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,610 in reported general payments places this provider in the 30th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 27 | $366,996 |
| RevlimidLenalidomide | 15 | $294,987 |
| IbrancePalbociclib | 13 | $207,577 |
| ImbruvicaIbrutinib | 11 | $183,749 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $170,497 |
| TafinlarDabrafenib Mesylate | 11 | $157,035 |
| EliquisApixaban | 83 | $55,512 |
| XareltoRivaroxaban | 14 | $18,169 |
| Abiraterone Acetate | 11 | $2,963 |
| Exemestane | 17 | $2,378 |
| Anastrozole | 132 | $2,027 |
| Hydroxyurea | 56 | $1,986 |
| Potassium Chloride | 21 | $1,534 |
| Letrozole | 40 | $1,145 |
| Dexamethasone | 37 | $1,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $53 | $366,99627 claims |
| NovartisMekinist, Tafinlar | $42 | $327,53222 claims |
| Bristol Myers SquibbRevlimid | $92 | $294,98715 claims |
| PfizerIbrance, Eliquis | $520 | $263,08996 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $70 | $183,74911 claims |
| Johnson & JohnsonXarelto | $52 | $18,16914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 25 medical oncology providers in Kansas.
Other medical oncology in Overland Park
- Ajjai AlvaOverland Park$25K
- Nisreen HaideriOverland Park$2K
- Anne OdeaWestwood$2.1M
- Benjamin GeorgeColby$433K
- Weijing SunWestwood$150K
- Anwaar SaeedWestwood$126K
- Elizabeth WulffWestwood$65K
- Joseph MooreWichita$41K
- Anis ToumehGarden City$40K
- Joaquina BarandaWestwood$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.